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ABSTRACT In this study, samples from the 2013–2016 West African Ebola virus out-
break from patients in Guinea with Ebola virus disease (EVD) were analyzed to dis-
cover and classify what other pathogens were present. Throat swabs were taken
from deceased EVD patients, and peripheral blood samples were analyzed that had
been taken from patients when they presented at the treatment center with acute
illness. High-throughput RNA sequencing (RNA-seq) and bioinformatics were used to
identify the potential microorganisms. This approach conﬁrmed Ebola virus (EBOV) in
all samples from patients diagnosed as acute positive for the virus by quantitative
reverse transcription-PCR in deployed ﬁeld laboratories. Nucleic acid mapping to
Plasmodium was also used on the patient samples, conﬁrming results obtained with
an antigen-based rapid diagnostic test (RDT) conducted in the ﬁeld laboratories. The
data suggested that a high Plasmodium load, as determined by sequence read
depth, was associated with mortality and inﬂuenced the host response, whereas a
lower parasite load did not appear to affect outcome. The identiﬁcations of selected
bacteria from throat swabs via RNA-seq were conﬁrmed by culture. The data indi-
cated that the potential pathogens identiﬁed in the blood samples were associated
with translocation from the gut, suggesting the presence of bacteremia, which tran-
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samples from patients with Ebola virus disease
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scriptome data suggested may induce or aggravate the acute-phase response ob-
served during EVD. Transcripts mapping to different viruses were also identiﬁed,
including those indicative of lytic infections. The development of high-resolution
analysis of samples from patients with EVD will help inform care pathways and the
most appropriate general antimicrobial therapy to be used in a resource-poor set-
ting.
IMPORTANCE Our results highlight the identiﬁcation of an array of pathogens in
the blood of patients with Ebola virus disease (EVD). This has not been done before,
and the data have important implications for the treatment of patients with EVD,
particularly considering antibiotic stewardship. We show that EVD patients who were
also infected with Plasmodium, particularly at higher loads, had more adverse out-
comes than patients with lower levels of Plasmodium. However, the presence of
Plasmodium did not inﬂuence the innate immune response, and it is likely that the
presence of EBOV dominated this response. Several viruses other than EBOV were
identiﬁed, and bacteria associated with sepsis were also identiﬁed. These ﬁndings
were indicative of bacterial translocation across the gut during the acute phase
of EVD.
KEYWORDS Ebola, Ebola virus disease, informatics, Plasmodium falciparum, RNA-seq,
bioinformatics, coinfection, ﬁlovirus, gene expression, host-pathogen interactions,
intracellular parasites, malaria
The 2013–2016 Ebola virus (EBOV) crisis in West Africa devastated the health careand wider infrastructures of many communities, and subsequent sporadic cases
associated with sexual transmission have been reported (1). The outbreak was unprec-
edented in scale, providing an opportunity for an in-depth analysis of infected humans
and observations of previously unknown aspects of EBOV biology. The epidemic
occurred at a time when high-resolution genomic analysis could be used to analyze
samples obtained from patients during the outbreak (2–4). Using these approaches,
viral genome evolution has been investigated (2), and the host immune response has
been shown to play an important role in the outcome of infection (5). Additionally,
differential cellular transcriptional proﬁles of blood samples from patients who pre-
sented at an Ebola virus treatment center have been shown to be associated with
an outcome of either survival or death. Differences in activation of natural killer cells
suggested a large acute-phase response and activation of the innate immune
response (4).
Many of the patients from West Africa who had Ebola virus disease (EVD) would
have had an underlying burden of infectious disease. Additionally, during an EVD
breakout, other infections may be present and/or translocate from one organ to
another, complicating disease and patient management and inﬂuencing infection
outcome. Guinea, where the 2013–2016 outbreak originated, experiences high levels of
malaria transmission (1 case per 1,000 population), with Plasmodium falciparum being
responsible for 100% of cases in 2013 (6). Plasmodium as a coinfection has been
implicated in the outcome of EVD (7), and a cohort study suggested that the presence
of Plasmodium was associated with survival (8). The presence of GB virus C (GBV-C)
(formally known as hepatitis G virus) was examined in 49 patients positive for EBOV from
Sierra Leone (9), where both survival and GBV-C status were found to be associated with
age (9). There have been several case reports of Gram-negative septicemia in patients with
EVD (10), although very little data exist regarding the frequency of this septicemia. How-
ever, the incidence of bacteremia appeared to be low upon clinic admittance (11). Assess-
ing the presence of bacterial infection of the blood from large numbers of patients
infected with high-consequence infections is complicated, particularly under ﬁeld
conditions of high containment, and the primary need is to provide an accurate
diagnosis of EBOV.
During the outbreak in Guinea, the European Mobile Laboratory provided a frontline
diagnostic service by testing blood samples for EBOV via quantitative reverse
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transcription-PCR (qRT-PCR) and for the presence of Plasmodium spp. by using an
immunochromatographic assay (12). Patients who tested positive for EBOV were ad-
mitted into the Ebola Virus Treatment Centre and treated according to guidelines from
Médecins Sans Frontières (13). These patients subsequently either went on to succumb
to EVD (hospitalized fatalities) or survived infection (hospitalized survivors). The Euro-
pean Mobile Laboratory archived large numbers of these leftover diagnostic samples,
primarily consisting of RNA. Additionally, oral throat swabs were taken from people in
the community who died (community deaths) to test for EBOV. Blood samples were
also taken from patients who were convalescent for EBOV to prove that these patients
were EBOV negative and thus could be discharged from the Ebola Virus Treatment
Centre.
A genomics approach was used to sequence nucleic acids present in the samples
and to map reads to microorganisms (not mapping to the human genome). Identiﬁ-
cation of transcripts to pathogens would be indicative of other microorganisms po-
tentially present in the blood of patients with EVD, indicating translocation from the
gut during the acute phase and reﬂecting underlying burdens of disease. The data
indicated that the genomics pipeline successfully identiﬁed and quantiﬁed the amount
of EBOV. The data suggested that the presence of Plasmodium had been underreported
based on the antigen capture test and highlighted how a genomics approach could
provide additional evidence of this parasite and connect it to an identiﬁed patient
sample—particularly for retrospective analyses. The study found that most patients
with acute illness on admittance to the Ebola Virus Treatment Centre already had
extensive evidence in their blood of nucleic acid mapping to bacteria (the blood should
have been effectively sterile), as well as nucleic acid mapping to viruses and parasites.
The types of microbes identiﬁed argued strongly for bacterial translocation across the
gut wall. These results have implications for the design of supportive care platforms,
including empirical antimicrobial use.
RESULTS
A genomics approach was used to determine whether other microorganisms were
present in samples from patients who tested positive for EBOV. To do this and to
optimize the approach, several different types of patient samples were used (Table 1).
These focused on oral swabs taken from people who had died in the community and
blood samples that were taken as diagnostic samples when patients presented at an
Ebola Virus Treatment Centre in Guinea. These patient cohorts were classiﬁed as
hospitalized fatalities and hospitalized survivors, depending on their outcome after the
sample was taken. All of these hospitalized patients in the study had acute EVD at the
time of sampling. The mean time between symptom onset (as reported by the patient)
was not signiﬁcantly different between the two cohorts (Fig. 1).
Blood samples were also taken from EVD patients convalescing from the disease
who were conﬁrmed EBOV negative by qRT-PCR. The latter group acted as a control
(uninfected group). The host blood transcriptome from this healthy convalescent group
TABLE 1 Summary details of patients from which RNA-seq data were selected for this
studya
Patient trait
Community
deaths
Hospitalized
fatalities
Hospitalized
survivors
Convalescent
controls
n 24 118 44 16
% male 29.1 40.1 29.5 93.75
Age range 1–70 yr 2 mo–80 yr 10 mo–68 yr 18–40 yr
Mean age (yrs) 33.35 28.44 33.10 30
EBOV CT
Range 12.37–31.85 12.08–26.55 15.77–31.60 NA
Mean 18.81 17.23 21.67 NA
aSamples with similar threshold cycle (CT) values were chosen, as this would indicate similar viral loads. It
was not possible to directly correlate CT values to viral load. NA, not applicable.
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was not signiﬁcantly different from a healthy control group of patients (4) who were
located in British Columbia (14). These healthy patients were temporally and spatially
distinct from the outbreak, indicating that the host blood transcriptomes from conva-
lescent and healthy controls were equivalent (4). We noted, however, that the collec-
tion of blood from the convalescent patients would have been in a more controlled
environment than the collection of blood from the patients with acute EVD.
Identifying the total spectrum of microbes present in the blood samples. Rather
than ﬁrst trying to identify separate pathogens, based on predetermined lists of
pathogens that could be potentially present in blood samples taken from individual
patients, an unbiased search approach was taken. Sequencing data from all the acute
patients with EVD and convalescent patients were pooled to ﬁrst determine which
pathogens were present, using a combination of de novo and reference-based mapping
approaches. The identiﬁed pathogens were then used to form a speciﬁc query database
at the individual patient level to determine which pathogens were present in which
samples, thus reducing computational time.
Sequence reads were combined from all the patients in these groups and any
that aligned to the human genome were removed from the analysis, leaving
approximately 1 TB of fastq data. Next, these reads were processed by using the
Trinity read normalization software before assembling into ~1.2 million contigs using
Trinity. These contigs were searched in BLAST using Diamond BLAST to ﬁnd the nearest
homologues and then they were manually searched to conﬁrm the presence of the
EBOV genome. As expected, a near-full-length genome corresponding to EBOV was
assembled by use of Trinity, allowing calibration and veriﬁcation of the approach. In
addition, evidence of genetic material belonging to other pathogens was identiﬁed
(provided as a fully searchable Excel ﬁle in Table S1 in the supplemental material and
abstracted in Fig. 2).
Examples are also presented in Table 2 (for bacterial, fungal, and parasitic patho-
gens) and Table 3 (for viral pathogens) to illustrate the mix of microorganisms and gene
products identiﬁed. The largest number of reads mapped to Acinetobacter spp. (prev-
alent in intensive care units), Echinococcus granulosus (a tape worm), Bacteroides fragilis
(a commensal bacterium associated with the normal ﬂora of the colon), Trichuris
trichiura (a whipworm normally found in the intestine), and Burkholderia multivorans
(a bacterium associated with chronic infections in cystic ﬁbrosis), followed by EBOV.
The data immediately illustrated the potential complexity of microorganisms in
acutely ill patients who are positive for EBOV and that these other organisms may
potentially confound treatment. Obvious from this effort was the identiﬁcation of
sequence reads mapping to Plasmodium falciparum, the causative agent of malaria
tropica. The presence of this parasite was also conﬁrmed by an antigen-based approach
(a rapid diagnostic test [RDT]) for many of the samples in the European Mobile
Laboratory deployed in Guinea.
The convalescent control group samples provided a control for potential
environmental contamination for blood sampling and the informatics assignment
pipeline. The convalescent control group provided a means to test the high-
FIG 1 Mean time between symptom onset and sample procurement for two of the three different
patient categories, hospitalized survivors and hospitalized fatalities.
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throughput RNA sequencing (RNA-seq) and bioinformatics approaches in terms of
sample handling and potential environmental contamination during the stages in-
volved in obtaining samples from patients, sample processing, and transport, all the
way through to sequencing. The prediction was that in the convalescent group of
patients that had been shown to EBOV negative by qRT-PCR and Plasmodium negative
through RDT, these and other organisms should not have been found, as blood is
effectively sterile. In this group of 16 patients, no transcripts mapping to Plasmodium
falciparum or to EBOV were identiﬁed. In only one patient were transcripts identiﬁed
that mapped to a bacterium, which was identiﬁed as Pseudomonas at the species level
(Fig. 3). These results thus suggest that any potential environmental contamination was
minimal and the informatics pipeline did not identify spurious “hits.”
Deﬁning the oral microbiome and selected conﬁrmation by mass spectrome-
try. Sequence analysis of the RNA prepared from swabs taken from community deaths
(n  24) illustrated a range of nucleic acids mapping to bacteria that would be expected
in the oral microbiome. This included sequence reads mapping to Neisseria meningitidis, a
Gram-negative bacterium that can cause sepsis (Fig. 4). A mass spectrometry-based ap-
proach was then used to conﬁrm the identiﬁcation of individual bacterial species in the oral
microbiome of patients in the community death cohort. Oral samples were cultured at
high containment facilities, and colonies were recovered from the throat swabs of ﬁve
separate patients in the community death group; these samples tested positive for
FIG 2 Illustrative examples for the total number of reads mapped to species identiﬁed in the blood
samples from patients with acute EVD.
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bacteria and fungi by mass spectrometry (Table 4). A score for the matrix-assisted laser
desorption ionization–time of ﬂight (MALDI-TOF) results between 2.000 and 2.2999
indicated secure genus identiﬁcation, and scores between 2.300 and 3.000 indicated a
high-probability species identiﬁcation. Identiﬁcation of bacteria by mass spectrometry
matched those identiﬁed by the RNA-seq and computational approaches. For example,
Proteus mirabilis was identiﬁed by RNA-seq and by mass spectrometry from swabs
taken from two patients, and Rothia mucilaginosa and Streptococcus salivarius were
identiﬁed in individual patients.
Identiﬁcation of transcripts mapping to bacteria in the blood of EVD patients
was indicative of bacterial translocation from the gut. Nucleic acids from both
bacteria (Table 2; Fig. 3) and fungi (Table 2) were identiﬁed in the blood from
EBOV-positive patients presenting at the Treatment Centre and testing positive for
EBOV. Conﬁrmatory blood cultures were attempted at high containment but were not
successful, possibly due to multiple freeze-thaw cycles and suboptimal sample trans-
port. Although it was problematic to distinguish what may be commensal microorgan-
isms from these data, nevertheless, several bacterial species were identiﬁed, based on
sequence reads mapped, that have been associated with disease in humans, particu-
larly sepsis (15). These species included Acinetobacter baumannii, which thrives in
individuals with weakened immune systems and is considered a nosocomial agent and
has multidrug resistance (16). Streptococcus pneumoniae and Haemophilus inﬂuenzae
are found asymptomatically in the upper airways of asymptomatic healthy carriers, but
if found in the bloodstream, both pathogens can cause pneumonia, meningitis, and
sepsis. Haemophilus inﬂuenzae was identiﬁed in both the blood (and swab) samples.
Several patients had evidence of a wide range of bacteria, based on nucleic acid
sequences identiﬁed, including one patient in the hospitalized survivors category. This
patient had evidence of nucleic acids that mapped to bacteria associated with sexual
transmission and vaginal infection, including Gardnerella vaginalis, Lactobacillus iners,
and Ureaplasma urealyticum. Nucleic acids from Enterobacteriaceae was also identiﬁed
in many patients. These are the predominant pathogenic bacteria in the bowel, where
TABLE 2 Exemplary data on the variety of microorganisms identiﬁed in pooled RNA-seq data from 179 patients positive for EBOV based
on qRT-PCR
Organism Protein % identity Alignment E value
Escherichia coli G58-1 Glycosyl transferase family 2 100 583 0.00E0
Lactobacillus fermentum DNA-directed RNA polymerase subunit beta 100 722 0.00E0
Wohlfahrtiimonas chitiniclastica Hypothetical protein, partial 100 583 0.00E0
Plasmodium falciparum UGT5.1 Hypothetical protein C923_00328 100 511 4.50E298
Candida albicans WO-1 Acetyl coenzyme A carboxylase 100 504 2.50E293
Streptococcus pneumoniae EU-NP04 Transposase DDE domain protein 100 493 2.90E292
Myroides spp. GMP synthase 100 508 3.20E292
Haemophilus inﬂuenzae Phosphoribosylformylglycinamidine synthase 100 500 1.80E289
Acinetobacter baumannii AB307-0294 2-Isopropylmalate synthase 100 479 1.20E276
Providencia rettgeri DSM 1131 DNA polymerase III subunit alpha 100 483 9.70E276
Plasmodium falciparum Vietnam Oak-Knoll Hypothetical protein PFFVO_04502 100 476 2.20E270
Ureaplasma urealyticum Cell division protein FtsH 100 478 8.20E264
Lactobacillus fermentum 6-Phosphogluconate dehydrogenase 100 457 3.70E260
Plasmodium falciparum Tanzania (2000708) Hypothetical protein PFTANZ_03315 100 450 5.70E260
Streptococcus sanguinis Collagen-binding protein 100 439 2.80E251
Acinetobacter baumannii Putrescine/spermidine ABC transporter 100 444 5.10E251
Haemophilus haemolyticus Catalase 100 415 8.40E250
Plasmodium falciparum 3D7 Elongation factor 1 alpha 100 433 4.60E249
Plasmodium falciparum MaliPS096_E11 Histidine-tRNA ligase 100 403 1.10E235
Myroides spp. Multispecies collagenase 100 413 6.20E232
Plasmodium falciparum Tanzania (2000708) ATP-dependent protease HslVU, ATPase subunit 100 410 2.10E229
Campylobacter spp. Multispecies GTP-binding protein 100 407 5.10E228
Streptococcus parasanguinis Amino acid transporter 100 402 8.80E228
Haemophilus parainﬂuenzae L,D-Transpeptidase 100 393 3.80E224
Escherichia coli Leucyl-tRNA synthetase 100 383 9.40E224
Myroides spp. Diaminopimelate decarboxylase 100 388 9.30E223
Myroides odoratimimus TonB-dependent receptor 100 389 1.80E222
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bacterial translocation would be expected to originate in EVD. Examples included
sequence reads mapping to Gram-negative bacteria such as Escherichia coli, Klebsiella
spp., Enterobacter spp., Shigella spp., Salmonella spp., Pseudomonas spp., and Gram-
positive bacteria such as Enterococcus spp. Therefore, the data indicate that most
patients with EVD sequenced in this study had evidence of bacterial translocation
across the gut.
The effect of bacteria on the host response in EVD patients. Analysis of the host
response in peripheral blood samples from patients with acute EVD identiﬁed several
differences compared to healthy controls (4). There were also differences in the host
transcriptomes between patients with EVD who survived versus those who succumbed
to EVD (4). These included pathways involved in the innate response, blood coagula-
tion, and the acute-phase response (4). To investigate whether the potential presence
of bacteria in the blood of patients with EVD inﬂuenced the host response, transcrip-
TABLE 3 Virus sequences identiﬁed in pooled RNA-seq data from 179 patients positive for EBOV based on qRT-PCR and clinical
diagnosis
Virus Protein % identity Amino acid length E value
EBOV L protein 96.8 2,212 0.00E0
GB-C Polyprotein 99.1 328 1.50E190
HHV-4 BALF2 100 100 1.9E51
LF2 protein 100 166 4.9E91
BALF5 98.8 172 4.4E88
BALF4 100 257 6.6E142
DNA polymerase catalytic subunit 99.2 131 2.3E71
BHRF1 100 121 7.4E-66
BARF0 99.2 120 6.5E62
Early antigen D 100 118 2E60
gp110 precursor 100 95 1.3E49
A73 protein 100 94 6.1E50
LF1 98.9 92 1.1E48
Putative BHLF1 protein 98.7 75 4.8E42
BFRF1 100 71 4.1E32
BMRF2 100 68 7.6E31
dUTPase 98.5 68 3E32
BFRF2 100 67 4.2E32
LF3 protein 100 45 0.0000000000000002
K15 100 37 0.00000000000056
HHV-5 (cytomegalovirus) IRL4 100 107 3.1E53
IRL3 94.1 101 1.20E46
IRL7 100 82 1.60E37
RL5A 63.6 66 9.30E15
IRL5 55.1 69 3.50E12
UL109 68.1 47 2.10E10
Hepatitis A virus Polyprotein 100 91 5.5E45
Hepatitis B virus Polymerase 92.8 503 3.30E278
Pepino mosaic virus Replicase 99.4 163 4.60E87
Sewage-associated gemycircularvirus-4 Replication-associated protein 100 105 3.60E57
Rotavirus A VP6 98.8 86 8.1E41
VP1 100 75 1.1E33
NSP3 169 251 1.5E21
Papillomavirus Minor structural protein- interacting protein 100 56 3.40E24
L2 97.2 72 1.50E34
Regulatory protein 98.5 67 5E30
Torque Teno virus 20 Unnamed protein product 100 32 9.10E9
Tobacco mosaic virus Replicase 97.2 1,521 0.00E0
Capsid protein 100 102 7.2E49
126-kDa protein 99 314 2.30E181
Movement protein 97.4 268 8.60E145
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tome changes in these exemplary pathways were compared between the different
groups of patients. This analysis made use of matching host transcriptome data that
had been determined for this group of patients (4). The abundance of transcripts
mapping to selected genes were chosen to assess the effect of pathogen burden on the
different exemplary pathways. The data indicated that certain transcripts associated
with the acute-phase response (intercellular adhesion molecule 1 [ICAM-1] and trans-
FIG 3 Heat map showing the bacterial species (y axis) identiﬁed by mapping to nucleic acids by comparing all patient cohorts who had a blood sample taken
when they had acute EVD. The x axis shows individual patients from the convalescent control group (green) (n 16), hospitalized survivors group (yellow) (n
44), and hospitalized fatalities group (orange) (n  118); data for these groups are also separated by vertical lines. The colors represent the arbitrary read depth
of the sequence, with yellow indicating a greater sequence read depth.
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forming growth factor 1 [TGF-1]) were present at different abundance levels in EVD
patients with versus without sequence reads mapping to bacteria in their blood (Fig. 5).
In contrast, there were no signiﬁcant differences in the abundance levels of selected
transcripts associated with blood clotting, interferon (IFN) stimulation, or inﬂammation,
at least in the limited sample sets used in this study.
Analysis of Plasmodium and correlation with outcome. Matching sequencing
reads to the Alveolata superphylum from the blood samples suggested that most
transcripts corresponded to P. falciparum (Fig. S1), and on a per-patient basis, the
presence of the malaria parasite was conﬁrmed by RDT. The data indicated that 84% of
FIG 4 Heat map showing the bacterial species (y axis) identiﬁed mapping to nucleic acids in a swab sample taken from an individual patient. All patients in
this category were deceased at the time of sampling (n  24). The color represents the arbitrary read depth of the sequence, with yellow indicating a greater
sequence read depth.
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blood and plasma samples contained sequence reads mapping to P. falciparum tran-
scripts. However, these sequence reads varied from an FPKM (a measure of sequence
read depth and abundance of RNA transcripts mapping to P. falciparum) of 59, in a
sample from a patient with acute EVD with the lowest number of sequences, to an
FPKM of 358820, representing the highest number of sequence reads mapping to
Plasmodium spp.
Comparison with the RDT results suggested that the presence of P. falciparum may
have been underrepresented in the sampled patient population (Fig. 6). The data were
then analyzed to investigate whether the P. falciparum load inﬂuenced the outcome of
EVD (Fig. 6). As the RDT is qualitative, sequence read depth was used as a proxy
measurement for the amount of Plasmodium present, and these results are akin to
those from qRT-PCR, which is used as a conﬁrmatory technique for the laboratory
diagnosis of malaria (17, 18). Here, sequence read depths were divided into arbitrary
bins based on approximately the same numbers of patients. Of the patients experi-
TABLE 4 Details of bacterial isolates from throat swab samples identiﬁed by mass
spectrometry approaches
EBOV CT Age Sex MALDI-TOF result(s)a
24 22 yr Male Proteus mirabilis (2.537)
19 33 yr Female Rothia mucilaginosa (2.181)
25 60 yr NDb Proteus mirabilis (2.427)
14 4 mo Male Staphylococcus aureus (2.378) Acinetobacter baylyi (2.054)
26 63 yr Male Streptococcus salivarius (2.117) Candida albicans (2.141)
aScoring for MALDI-TOF results was as follows: 3.000 to 2.300, highly probable species identiﬁcation; 2.2999
to 2.000, secure genus identiﬁcation.
bND, no data.
FIG 5 Relative abundance of transcripts mapping to host transcripts associated with pathways involved
in the acute-phase response, blood clotting, innate immune response, and inﬂammation in patients with
EVD (positive by RNA-seq and qRT-PCR) who were conﬁrmed positive (n  22; gray) or negative (n  9;
black) for at least one bacterial coinfection (by RNA-seq). Relative gene expression levels were measured
as fragments per kilobase of transcript per million mapped reads (FPKM). Each of the graphs presented
is based on the average FPKM values. Statistical analysis was performed using a two-way ANOVA with
Sidak’s multiple-comparisons adjustment (Prism 7; GraphPad, CA).
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encing the highest reads mapping to P. falciparum, 87% succumbed to a fatal infection
(n  6). However, while the data indicated that in general mortality increased with
sequence read depth, there was no absolute correlation, at least at the sequence read
depths measured in this analysis.
The effect of P. falciparium on the host response in EVD patients. For EVD
patients with the highest depth of sequence mapping to P. falciparum, the host response
may have been different for patients infected only with EBOV. To investigate this, the
abundance of transcripts corresponding to markers of innate immunity and associated
with malaria tropica were compared. The two groups of patients selected were patients
with EBOV that were positive for P. falciparum, determined by both RNA-seq and RDT
and using data from patients with the highest mapped reads to P. falciparum (n  10),
versus patients with EBOV but for whom both RDT and sequence read results were
negative for P. falciparum (n  13). This analysis made use of matching host transcrip-
tome data that had been determined for this group of patients (4). Selected genes were
chosen whose abundance levels had previously been associated with severe malaria
tropica in the absence of EBOV infection (IFIT2, IFIT3, IFITM3, ISG15, STAT1, MX1, TGF-,
PRF1, PGRMC1, CTSW, ICAM-1, CD36, IFN-, interleukin-10, and IFN regulatory factor 9)
(19–22). The abundance levels of the gene transcripts were compared, and these data
are presented in two ways (Fig. 7). The ﬁrst way shows the mean value plus the
standard deviation for each transcript. The second way shows the median value plus
the total range; the latter analysis is additionally presented because the transcript
abundance in individual patients did not follow a normal distribution. The data
indicated no signiﬁcant differences in the abundance of transcripts associated with the
innate response between patients who were EBOV positive and P. falciparum negative
compared to patients who were positive for both EBOV and P. falciparum. This
suggested that P. falciparum has no additional effect on the innate response. A similar
analysis was performed on the abundance of transcripts associated with the coagula-
tion pathway (FGA, FGB, FGG, FGL1, and ALB) (Fig. 8). These were the most differentially
regulated transcripts between the EVD and control groups (4). The data indicated that
transcripts associated with the coagulation pathway were increased in abundance in
several of the EVD patients who tested negative for P. falciparum, compared to EVD
patients who tested positive for P. falciparum. Note that this analysis was based on a
limited patient sample size (23 in total) due to the stringent inclusion criteria used.
Nucleic acids from viruses were identiﬁed in the blood of patients with EVD.
Nucleic acid mapping to several different viruses were identiﬁed in the blood of EVD
patients. These included GB virus C, human herpesvirus 4 (HHV4, or Epstein-Barr virus),
human herpesvirus 5 (cytomegalovirus), and rotavirus. The latter virus is associated with
FIG 6 Effect of an increased number of reads mapping to P. falciparum. The green line, associated with
the right-hand y axis, shows the proportion of patients who tested negative for malaria according to the
RDT but for whom reads to P. falciparum were detected during RNA-seq analysis. The red line, also
associated with the right-hand y axis, shows the patient fatality rate according to different levels of reads
to P. falciparum. The left-hand y axis shows the abundance of patients in each bin, i.e., the number of
individuals who were grouped into each category. The graph was created using Prism (GraphPad, CA).
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gastroenteritis and may be present in the blood through gastrointestinal bleeding (23)
and has been associated with extraintestinal disease (24). No evidence was found in the
samples for common circulating respiratory viruses. Data indicated that in approxi-
mately 30% of the samples, nucleic acid mapping to HHV4 was identiﬁed. The identi-
ﬁcation of BALF2 mRNA transcript from HHV4 (Table 3) implies there was HHV4
activation in EVD patients (25). In contrast to a previously report (9), in our patient
sample set we found no correlation between the presence of nucleic acid from GBV-C
virus and survival. However, our sample population included only 5 patients identiﬁed
to have nucleic acid from GBV-C, with only 3 of these samples have been obtained
FIG 7 Relative abundance of transcripts mapping to host transcripts associated with malaria and the
innate immune response in patients with EVD who were conﬁrmed positive (gray; n  10) or negative
(black; n  13) for P. falciparum (by RNA-seq and RDT). Relative gene expression levels were measured
as the fragments per kilobase of transcript per million mapped reads (FPKM). Each set of graphs (left and
right) is based on average FPKM values. Two analyses of the data are presented, and means and standard
deviations (left) or medians and total ranges (right) are shown.
FIG 8 Relative abundance of transcripts mapping to host transcripts associated with coagulation in
patients with EVD and conﬁrmed positive (gray; n  10) or negative (black; n  12) for P. falciparum (by
RNA-seq and RDT). Relative gene expression levels were measured as fragments per kilobase of transcript
per million mapped reads (FPKM). The graphs are based on average FPKM values. Two analyses of the
data are presented, showing the means and standard deviations (left) and medians and total ranges
(right).
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during acute infection with EBOV. Nucleic acid mapping to HHV4 was most prevalent
in the 1- to 4-years age group category (as was P. falciparum), whereas nucleic acid
mapping to GBV-C virus appeared more prevalent in older age groups (Fig. 9). Some-
what surprisingly, several plant virus genomes/transcripts were also identiﬁed, with the
highest and most conﬁdent hit being tobacco mosaic virus (TMV), for which the full
genome was recovered. Our review of the literature suggested that serum antibodies
to TMV can be identiﬁed in humans (26). Taken at face value, our data set suggest that
plant virus genomes (and, by implication, plant viruses) can be found in blood, and this
ﬁnding again may be indicative of a breakdown in the integrity of the gut wall.
However, environmental contamination cannot be ruled out, especially during sample
gathering. However, we note that at least for sequencing, none of the staff was
cigarette or cigar smokers, and no plants were grown in the laboratory area.
DISCUSSION
This study investigated the presence of transcripts from viral, bacterial, fungal, and
parasitic pathogens in patients infected with EBOV. The study made use of samples
taken for routine diagnostic testing for EVD. This is the ﬁrst systematic analysis of
pathogens in patients infected with EBOV based on an unbiased deep sequencing
approach. This approach did not rely on speciﬁc ampliﬁcation of pathogens in selected
growth media or enrichment of genomic sequences (e.g., by RT-PCR or PCR). Samples
included those taken from patients acutely ill with laboratory-conﬁrmed EVD infection
prior to being admitted to the Ebola Virus Treatment Centre. Most of these patients
were admitted around 6 days into the illness (based on when the patient thought they
started feeling unwell) (Fig. 1). This was still early in the disease course, but based on
clinical studies the majority of patients would be predicted to have entered the
gastrointestinal stage of illness (which occurs after 3 days [27, 28]), and therefore may
also be predicted to have bacterial translocation from the gut to the blood. Blood
samples taken from convalescent patients were used as a control to establish back-
ground levels of transcripts mapping to pathogens. As noted, the taking of blood from
this group of patients would have been different from that from patients with acute
EVD. This may have had an impact on which microbes were present, although we note
that there was no one uniform microbial signature in the blood from patients with
acute EVD. In the main, blood samples were used for the analysis presented herein,
although some plasma sample results were also incorporated. There may be subtle
differences in the transcriptome mapping to nucleic acids from pathogens in these
samples, as sequence reads from blood would map to both extra- and intracellular
pathogens, whereas with plasma, sequence reads would be predicted to map to
extracellular pathogens.
The presence of other microorganisms can have a signiﬁcant impact on the mor-
bidity and mortality associated with primary infection. In a recent study, parasitemia
(not clinical malaria) was positively associated with survival in patients with EVD (8).
FIG 9 The presence of nucleic acids from certain viruses varies with patient age. Patients were grouped
according to their immunological maturity (1 year [n  8], 1.5 to 4 years [n  13], 5 to 45 years [n 
120], and 46 years [n  39]), and the proportions of each group with reads mapping to P. falciparum,
HHV4, and GBV-C are shown.
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This study used PCR-based approaches to identify the presence of P. falciparum. Data
from the analysis of samples gathered by the European Mobile Laboratory suggested
that high parasite load (as determined by RDT, which likely indicates clinical malaria)
corresponded with a poor outcome in children between 5 and 14 years old (12). The
deep sequencing analysis suggested a larger proportion of patients with EVD had
sequence reads mapping to P. falciparum than was recorded by use of RDT. P. falci-
parum RDTs have a limited sensitivity and therefore mainly detect patients with higher
levels of parasites in the blood, as found with acute malaria disease. Molecular
techniques have shown a high background prevalence of Plasmodium (29).
The effect of Plasmodium on patient outcome with this data set varied according to
the method by which Plasmodium status was determined (Fig. 6). Via the RDT, Plas-
modium appeared to impact patient outcome (P  0.053; analysis of variance [ANOVA]
performed using software from SPSS, Inc.). However, this effect was eliminated once
P. falciparum status was conﬁrmed using RNA sequencing data. This could be because
with RNA-seq a larger proportion of individuals in the sample population tested
positive for P. falciparum: 84% (156 out of 186) compared to 33% (40 out of 121) by RDT.
The discrepancy between RDT and RNA-seq data was reduced as the number of reads
to Plasmodium spp. increased. The RDT detects patients with high parasitemia and
misses patients with low parasite levels. Thus, it is not surprising that a high Plasmo-
dium spp. load has an impact on patient outcome, whereas a low Plasmodium load has
a less pronounced effect or no impact. Individuals with a high Plasmodium load are
likely to have been sampled at the time they were experiencing the acute phase of the
infection. Acute-phase infections are associated with strong systemic proinﬂammatory
responses (30), which are known to have antiviral effects. One hypothesis is that these
responses may also act synergistically with virus-induced immunopathogenic re-
sponses. People with a low parasite load load are likely to harbor a chronic asymp-
tomatic infection, which is characterized by mild or no inﬂammation and thus might be
predicted not to interfere with Ebola virus infection. This was investigated by compar-
ing the abundance of gene transcripts associated with the innate response stimulated
by P. falciparum in EBOV-positive patients who had the highest sequence read depth
mapping to P. falciparum and were also RDT positive, versus EBOV-positive patients
who had no reads mapping to P. falciparum and were also RDT negative. The analysis
made use of matched transcriptomic data to investigate the host response to EBOV
infection (4). Overall, there was no signiﬁcant difference in the abundance of gene
transcripts associated with the innate response (Fig. 7), but there were potential
differences in the abundance of transcripts associated with blood coagulation (Fig. 8).
We note, however, that this analysis was based on a limited number of patients with
matched host transcriptome data.
Nucleic acids from several bacterial species were identiﬁed in the blood and plasma
samples from patients with EVD (Fig. 3). Sequence reads mapping to multiple organ-
isms were identiﬁed in the patient samples, for example, Prevotella a genus of Gram-
negative bacteria. Several studies have found that Prevotella dominates the African gut
microbiome (31, 32), giving credence to the hypothesis of the translocation of bacteria
from the gut to the blood. However, across both hospitalized survivors and hospitalized
fatalities, in a minority of patients there was no evidence of nucleic acids from bacteria,
at least at the sequence read depths used in this study. Additionally, the approach did
not provide antimicrobial sensitivity or clear identiﬁcation of dominant causative
organisms in a polymicrobial picture. The use of data generated by mapped reads on
bacterial identiﬁcation should be treated with some caution, due to the close phylo-
genetic relationships between nonpathogenic and pathogenic representatives of a
species. However, many of the identiﬁed bacteria are associated with sepsis, and
consideration should be given to appropriate antibiotic therapy. Clinical guidelines
suggest empirical antibiotic treatment for patients with EVD who often present with
nonspeciﬁc symptoms and signs that are difﬁcult to distinguish from malaria, typhoid
fever, or bacterial sepsis (33). The rationale for empirical antibiotic therapy in EVD is
2-fold. First, it is used to provide broad-spectrum antibiotic cover for suspected EVD
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patient who have a range of infectious diseases, recognizing the lack of diagnostic
capacity and resources in Ebola Treatment Centres. Second, it is to provide empirical
Gram-negative/anaerobic antibiotic cover for patients with conﬁrmed EVD who are at
risk of secondary bacteremia, which is thought to originate from translocation across
the bowel wall that is associated with the gastrointestinal clinical stage of EVD. Most
patients showed evidence of nucleic acids from Pseudomonas in their blood, and
supportive antibiotic therapy should take into account the possible presence of this
bacterial species.
Unsurprisingly, oral swab samples from community deaths indicated bacterial di-
versity and bacterial load and were included for completeness (Fig. 4). This technique
became routinely utilized in standard postmortem pathological sampling during this
outbreak, with recognized limitations. The bacteria present in this sample set, and their
growth, may be reﬂective of agonal processes or may represent growth postmortem.
These samples included Wohlfahrtiimonas chitiniclastica, which was likely deposited by
ﬂies postmortem, and Neisseria meningitidis, a causative agent of meningitis, which was
identiﬁed in both blood samples and swabs. Mass spectrometry also conﬁrmed the
identiﬁcation of some of the species in throat swabs, thus validating the sequencing
and bioinformatics approaches. Note that it was not possible to directly compare a
throat swab with a blood sample from the same patient. Throat swabs were only used
in the community deaths category, and only blood samples were taken when the
patient presented at the treatment center. The species identiﬁed by mass spectrometry
included bacteria and fungi. These microorganisms can be found as transitional ﬂora in
the upper respiratory tract. However, in case of a weakened immune system, these
opportunistic pathogens may cause bacterial sepsis, pneumonia, or bacteremia. The
successfully cultured bacteria are likely to constitute only a small part of the real
bacterial ﬂora, but many of the bacteria and fungi cannot be cultured due to the long
storage time at80°C and repeated freeze-thaw cycles. This illustrates the versatility of
the sequencing pipeline that only requires RNA, returning large overlapping data sets
and not requiring multiple steps at high containment.
Nucleic acids from several viruses were identiﬁed that correlated with the age of the
patient, such as HHV4 (Epstein-Barr virus) (Fig. 9). No evidence was found to suggest
that, of the viruses potentially identiﬁed, there was a correlation with outcome or that
any virus had a synergistic effect. One transcript corresponding to the envelope
glycoprotein of human immunodeﬁciency virus 1 (HIV-1) was found (Table S1), but no
other HIV-1 transcripts were identiﬁed. The prevalence of adult HIV-1 in Guinea is 1.7%
(2012 estimate). Therefore, in the patient cohort examined in this study, we would have
predicted approximately 3 cases. However, if the virus was present in low copy number,
then possibly higher sequence read depths would have been required to identify HIV-1.
In addition, more specialist approaches are required to reliably identify HIV-1 and
assembly genomes and rely on preampliﬁcation (34). The evidence suggested potential
activation of HHV4, and this could contribute to T cell dysfunction in these patients and,
as noted, immune cell subsets may have different frequencies in different patients
with EVD.
The deep sequencing and bioinformatics approaches showed that nucleic acids
from viral, bacterial, fungal, and parasitic organisms were present in the blood taken
from many patients. Many of the potentially identiﬁed bacteria are associated with
sepsis and consideration should be given to treating patients with antibiotic therapy.
While Plasmodium spp. can be detected by the applied rapid test under ﬁeld condi-
tions, the deep sequencing data suggest that this approach did not detect normal
parasite carriage in the EBOV-infected patient population, and this may have affect on
lethality calculations.
This is the ﬁrst study to demonstrate that a potential range of pathogens are present
in the blood of patients with EVD and provide evidence for existing treatment guide-
lines (antimicrobial therapy). The study provides a comprehensive open access data set
for researchers to investigate a range of microbial factors linked to EBOV pathogenesis
and outcome. Although we have learned much about the clinical syndrome of EVD and
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natural history of the disease, the pathogenesis of disease is still not understood. Much
of the research focus focused on the 2013–2016 outbreak has been with regard to
developing clinical trials for EBOV-speciﬁc therapeutics, but little evidence exists for
different supportive care platforms, including empirical antimicrobial use. Deep se-
quencing of historical samples from patients can help ﬁll this vital knowledge gap and
illustrates research requirements for future EBOV outbreaks, mainly to build in pro-
spective, preapproved protocols for EVD with serial sampling, matched clinical data,
and correlation with other standardized microbiological techniques.
MATERIALS AND METHODS
Patients. Four main categories of patients were selected for analysis (Table 1). In the ﬁrst two groups,
RNA was extracted from (mainly) blood or plasma samples, taken from acutely ill patients during
assessment of potential EVD cases, by the European Mobile Laboratory, located in the Médecins Sans
Frontières (MSF) Ebola Treatment Centre Guéckédou in Guinea. These patients either went on to survive
(hospitalized survivors, n  44) or had a fatal infection (hospitalized fatalities, n  118). These patients
were also tested for Plasmodium. For the latter analysis, noninactivated EDTA blood was applied to an
immunochromatographic assay (BinaxNOW Malaria; Alere GmbH, Cologne, Germany). These acute
patients were treated according to MSF guidelines. In the third category, RNA was prepared from blood
samples taken from patients who were convalescent for EVD and were qRT-PCR negative for EBOV
(convalescent controls, n  16). In a fourth group, RNA was extracted from oral and throat swabs taken
from people who had already died of EVD (community deaths, n  24). This last group was selected to
evaluate microbiome sampling using swabs, as these are a suggested alternative to peripheral blood for
determining EBOV status or an alternative to cardiac puncture blood for deceased patients. All RNA was
stored at 20°C until shipment.
The National Committee of Ethics in Medical Research of Guinea approved the use of diagnostic
leftover samples and corresponding patient data for this study (permit number 11/CNERS/14). Ethical
permission for the sequencing work conducted at the University of Liverpool on RNA from patient
samples was reviewed and approved by the institution under reference number RETH000784. Permission
to sequence biological samples (made safe) containing genetic material from human pathogen hazard
group 4 viruses was granted by the UK Home Ofﬁce and the United Kingdom National Counter Terrorism
Security Ofﬁce. Ethical permission was also obtained from the Ethik-Kommission Der Arztekammer
Hamburg (PV4910). Experimental methods complied with the Helsinki Declaration. For samples obtained
from community deaths, hospitalized survivors, and hospitalized fatalities, these samples were collected
as part of the public health response to contain the outbreak in Guinea, and informed consent was not
obtained from these patients. For samples from convalescent patients, informed consent was obtained.
There was no signiﬁcant difference between onset of symptoms (as reported by the patient) and
sample procurement for admittance into the Ebola Treatment Centre (Fig. 1).
RNA sequencing and bioinformatics. Extracted RNA was DNase treated and sequenced using a
HiSeq2500 system, with no preampliﬁcation of any sequence, as described elsewhere (2, 35) and
reproduced herein. Samples from patients were sequenced on a HiSeq2500 system, and several criteria
were applied to the selection of data postsequencing. The RNA was DNase treated using Ambion Turbo
DNase. RNA-seq libraries were prepared from the DNase-treated RNA by using the Epicentre ScriptSeq
v2 RNA-seq library preparation kit and performing 10 to 15 cycles of ampliﬁcation. Libraries were puriﬁed
using AMPure XP beads. Each library was quantiﬁed using Qubit, the size distribution was assessed using
the Agilent 2100 Bioanalyser, and the ﬁnal libraries were pooled in equimolar ratios. The quantity and
quality of each pool were assessed with the Bioanalyzer and subsequently by qPCR using the Illumina
library quantiﬁcation kit from Kapa on a Roche Light Cycler LC480II system according to the manufac-
turer’s instructions. The template DNA was denatured according to the protocol described in the Illumina
User Guide and loaded at 12 pM. To improve sequencing quality control, samples were spiked with 1%
PhiX. The sequencing was undertaken on the Illumina HiSeq 2500 with version 4 chemistry, generating
2- by 125-bp paired-end reads. Base calling and demultiplexing of indexed reads were performed by
using Casava version 1.8.2 (Illumina) to produce all the sequence data in fastq format. The raw fastq ﬁles
were trimmed to remove Illumina adapter sequences by using Cutadapt version 1.2.1. The option -O 3=
was set, so that the 3= ends of any reads which matched the adapter sequence over at least 3 bp were
trimmed off. The reads were further trimmed to remove low-quality bases, using Sickle version 1.200 with
a minimum window quality score of 20. After trimming, reads shorter than 10 bp were removed.
Resulting sequence reads were initially mapped to the human genome using the short-read mapper
Bowtie2 as previously described (2). Those that did not map to the human genome were then pooled
and mapped again to a list of known human transcripts again using Bowtie2. Sequences that did not
align to either the human genome or human transcriptome were pooled, but the size of the data set
(~1 TB of fastq reads) required them to be preprocessed ﬁrst by the Trinity read normalization software
to reduce the memory requirements and runtimes prior to de novo assembly using Trinity (36). The
assembled data from Trinity were ﬁrst manually checked to determine that the EBOV genome had been
assembled before all the reads were checked for matches using Diamond BLASTX analysis against the
nonredundant protein database (37). Vertebrate BLASTX hits, including some for several nonhuman
primates, were excluded, as these were deemed likely high-copy human sequences which had passed
through the previous ﬁlters. Thirty-two contigs with a top hit to Medicago sativa (alfalfa) were also
excluded, as these had a taxonomically diverse array of matches with similar E values, indicative of
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spurious annotation. For each transcript, the best hit was retained and the protein name and organism
for that hit was associated with the transcript using in-house scripts. Quality and primer trimmed reads
were used as input for MetaPhlAn 2 for estimating genome coverage of bacterial species for each sample.
In general, for viral species a 20% mapping to a transcriptome was adopted as a threshold for positive
identiﬁcation.
Mass spectrometry analysis. Selected EBOV-positive samples underwent bacterial cultivation under
biosafety level 4 conditions, including samples of whole blood and throat swabs. The samples were
inoculated into bouillon broth enriched with 10% fetal bovine serum, incubated at 37°C in the presence
of 5% CO2, and after 24 h, 48 h, and 72 h the samples were plated onto blood agar. The mixed cultures
were isolated and underwent three subculture passages on blood agar. Colonies were identiﬁed from
throat swabs, but not from peripheral blood samples, and the colony samples were analyzed by
MALDI-TOF (Bruker MALDI Biotyper).
Accession number(s). Raw sequence read data for all the samples used in this analysis were
deposited with NCBI, BioProject ID PRJNA352396. Note that the data contain no patient-identiﬁable
information, only the outcome of infection.
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